Investments
407Portfolio Exits
81Funds
18Partners & Customers
2About Sofinnova Partners
Sofinnova Partners is a European venture capital firm specializing in Life Sciences. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs. The company was founded in 1972 and is based in Paris, France.
Expert Collections containing Sofinnova Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Sofinnova Partners in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Sofinnova Partners News
Dec 6, 2023
2h agoPrivate EquityAlternative InvestmentalternativeswatchViews: 61 Sofinnova Partners launched Sofinnova.AI, an artificial intelligence platform designed to uncover novel insights and boost life sciences innovation. Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN
Sofinnova Partners Investments
407 Investments
Sofinnova Partners has made 407 investments. Their latest investment was in T-Therapeutics as part of their Series A on November 11, 2023.
Sofinnova Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/15/2023 | Series A | T-Therapeutics | $59.85M | Yes | 1 | |
10/26/2023 | Series A | Betteromics | $20M | Yes | SHAKTI, and Triatomic Capital | 2 |
10/26/2023 | Seed VC | L'école AI | $3M | Yes | Preston-Werner Ventures, and Undisclosed Angel Investors | 3 |
10/18/2023 | PIPE - II | |||||
10/12/2023 | Seed VC |
Date | 11/15/2023 | 10/26/2023 | 10/26/2023 | 10/18/2023 | 10/12/2023 |
|---|---|---|---|---|---|
Round | Series A | Series A | Seed VC | PIPE - II | Seed VC |
Company | T-Therapeutics | Betteromics | L'école AI | ||
Amount | $59.85M | $20M | $3M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | SHAKTI, and Triatomic Capital | Preston-Werner Ventures, and Undisclosed Angel Investors | |||
Sources | 1 | 2 | 3 |
Sofinnova Partners Portfolio Exits
81 Portfolio Exits
Sofinnova Partners has 81 portfolio exits. Their latest portfolio exit was LimFlow on November 01, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/1/2023 | Acquired | 4 | |||
10/17/2023 | Acquired | 2 | |||
9/15/2023 | IPO | Public | 3 | ||
Date | 11/1/2023 | 10/17/2023 | 9/15/2023 | ||
|---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 4 | 2 | 3 |
Sofinnova Partners Acquisitions
1 Acquisition
Sofinnova Partners acquired 1 company. Their latest acquisition was NovusPharma on September 20, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/20/1999 | Convertible Note | Management Buyout | 1 |
Date | 9/20/1999 |
|---|---|
Investment Stage | Convertible Note |
Companies | |
Valuation | |
Total Funding | |
Note | Management Buyout |
Sources | 1 |
Sofinnova Partners Fund History
18 Fund Histories
Sofinnova Partners has 18 funds, including Sofinnova Industrial Biotech II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
11/17/2021 | Sofinnova Industrial Biotech II | $169.61M | 1 | ||
10/19/2021 | Sofinnova Capital X | $549.69M | 1 | ||
7/13/2021 | MD Start III | $75M | 2 | ||
3/3/2021 | Sofinnova Crossover Fund | ||||
10/17/2019 | Sofinnova Capital IX |
Closing Date | 11/17/2021 | 10/19/2021 | 7/13/2021 | 3/3/2021 | 10/17/2019 |
|---|---|---|---|---|---|
Fund | Sofinnova Industrial Biotech II | Sofinnova Capital X | MD Start III | Sofinnova Crossover Fund | Sofinnova Capital IX |
Fund Type | |||||
Status | |||||
Amount | $169.61M | $549.69M | $75M | ||
Sources | 1 | 1 | 2 |
Sofinnova Partners Partners & Customers
2 Partners and customers
Sofinnova Partners has 2 strategic partners and customers. Sofinnova Partners recently partnered with Apollo on May 5, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/16/2022 | Partner | United States | Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership . | 2 | |
2/28/2018 | Partner |
Date | 5/16/2022 | 2/28/2018 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | United States | |
News Snippet | Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences NEW YORK & PARIS -- -- Apollo and Sofinnova Partners , a leading European life sciences venture capital firm based in Paris , London , and Milan , today announced a long-term strategic and financial partnership . | |
Sources | 2 |
Sofinnova Partners Team
12 Team Members
Sofinnova Partners has 12 team members, including current Chief Financial Officer, Christophe Blanche.
Compare Sofinnova Partners to Competitors
BioCapital Europe is a life sciences investment conference that offers VCs and institutional investors unique and timely access to biotech, medtech, and diagnostics companies from the Benelux and Europe. It is based in Amsterdam, Netherlands.
Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.
Sofiouest is an investment and holding company that invests in digital innovation, development-transmission capital, and business real estate. Beyond equity investments in companies, Sofiouest invests indirectly in seed or growth funds. It was founded in 1985 and is based in Paris, France.
Medilink UK is a membership-based professional association and consulting firm that focuses on life science company growth. It uses the combined strengths of its regional partners to assist the growth and development of the life sciences commercial, academic, and clinical communities across the UK. It provides services to the medical device, pharmaceutical, and biotechnology industries. It was founded in 2005 and is based in Nottingham, United Kingdom.
Syncona Partners (LON: SYNC) is an investment company. The company offers services that include founding, building, and funding companies. It makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. The company was founded in 2012 and is based in London, U.K.
Dutch Life Sciences Conference brings together creative entrepreneurs and expert investors. It is hosted by organisations and companies whose mission is to help realize the further development and growth of the Dutch life sciences industry. It is based in Lisse, The Netherlands.
Loading...